Supplemental disclosures of cash flow information: Supplemental Cash Flow Information [Abstract] Customer [Domain] Customer [Domain] Vested (in shares) Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested in Period Restricted Stock Units Unvested Unvested Restricted Stock Units [Member] Unvested share instrument which is convertible to stock or an equivalent amount of cash, after a specified period of time or when specified performance conditions are met. Leasehold improvements Leasehold Improvements [Member] Net loss Net loss Net loss Net Income (Loss) Attributable to Parent Interest and other expense, net Interest And Other Income, Net Interest And Other Income, Net Right-of-use assets, net Right of use assets Operating Lease, Right-of-Use Asset Risks and Uncertainties [Abstract] Risks and Uncertainties [Abstract] Accrued compensation Employee-related Liabilities, Current Income Statement Location [Axis] Income Statement Location [Axis] Less: accumulated amortization Finite-Lived Intangible Assets, Accumulated Amortization Statistical Measurement [Domain] Statistical Measurement [Domain] Exercise of warrants (in shares) Class of Warrant or Right, Warrants Exercised The number of class of warrant or right exercised. Debt Maturity Schedule of Maturities of Long-term Debt [Table Text Block] Accrued balances - Accounts payable and accrued expense Accrued distribution expenses Accounts Receivable Allowances and Accruals - Accounts Payable and Accrued Expenses For an unclassified balance sheet, a valuation of sales allowance for receivables due a company that are expected to be uncollectible, classified within Accounts payable and other accrued expenses. Royalty receivable Cumulative Royalty Receivable Cumulative sum of the carrying amounts of royalty receivable as of the balance sheet date. Number of guaranteed royalty payments Number Of Guaranteed Royalty Payments Number Of Guaranteed Royalty Payments Security Exchange Name Security Exchange Name Entity Incorporation, State or Country Code Entity Incorporation, State or Country Code Forfeited (in dollars per share) Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Forfeitures, Weighted Average Grant Date Fair Value Revenue from Contract with Customer [Abstract] Royalty Obligation Activity Royalty Obligation Activity [Table Text Block] Royalty Obligation Activity Other non-current assets Total other non-current assets Other Assets, Noncurrent At-the-Market Offering At The Market Offering [Member] At The Market Offering Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table] Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table] Expected dividend yield Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Dividend Rate Net decrease in cash and cash equivalents Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect Acquired Finite-Lived Intangible Assets [Line Items] Acquired Finite-Lived Intangible Assets [Line Items] Computer, network equipment and software Computer, Network Equipment and Software [Member] Assets which are related to computer, network equipment and software. Entity File Number Entity File Number Repurchase price percentage Debt Instrument, Redemption Price, Percentage Expected volatility Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Volatility Rate 2024 Long-Term Debt, Maturity, Year Two Share-based compensation expense APIC, Share-based Payment Arrangement, Increase for Cost Recognition Remainder of 2022 Long-Term Debt, Maturity, Remainder of Fiscal Year Subsequent Event Type [Domain] Subsequent Event Type [Domain] Lessee, Lease, Description [Line Items] Lessee, Lease, Description [Line Items] Elective redemption percentage of debt Elective redemption percentage of debt Elective redemption percentage of debt. Organization, Consolidation and Presentation of Financial Statements [Abstract] Organization, Consolidation and Presentation of Financial Statements [Abstract] Amortization expense Amortization of Intangible Assets Stand Alone Product Stand Alone Product [Member] Stand Alone Product Payments for loan acquisition costs Payments of Financing Costs Lincoln Park Purchase Agreement Lincoln Park Purchase Agreement [Member] Lincoln Park Purchase Agreement Senior Secured Notes Due 2025 - First Additional Offering First Additional Offering [Member] The first additional offering of the loan agreement. Variable lease expense Variable Lease, Cost Total potentially antidilutive derivatives excluded from losses per share (in shares) Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount Inventory, Net Schedule of Inventory, Current [Table Text Block] Research and development Research and Development Expense [Member] Put Option Put Option [Member] Sale of Stock [Axis] Sale of Stock [Axis] Subsequent Events [Abstract] Subsequent Events [Abstract] Granted (in dollars per share) Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period, Weighted Average Grant Date Fair Value Award Type [Domain] Award Type [Domain] Finite-Lived Intangible Assets, Net, Amortization Expense, Fiscal Year Maturity [Abstract] Finite-Lived Intangible Assets, Net, Amortization Expense, Fiscal Year Maturity [Abstract] Liability related to the sale of future revenue, net at December 31, 2021 Liability related to the sale of future revenue, net (includes current portion of $1,732) Liabilities, Sale of Future Royalties Liabilities, Sale of Future Royalties Premium on early retirement of debt Premiums Paid, Early Retirement of Debt Premiums Paid, Early Retirement of Debt Local Phone Number Local Phone Number Credit Facility [Domain] Credit Facility [Domain] Assets Assets [Abstract] 2025 Long-Term Debt, Maturity, Year Three Exercisable at end of period (in shares) Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Number Vested or expected to vest at end of period (in dollars per share) Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Exercise Price Loans payable, current Loans Payable, Current Granted (in shares) Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Grants in Period Intangible Assets, Net Goodwill and Intangible Assets Disclosure [Text Block] Concentrations of risk Concentration Risk, Percentage Number of annual royalty payments receivable Number of Annual Royalty Payments Receivable Number of annual royalty payments receivable by the entity for the use of its rights and property by another party. Outstanding at beginning of period (in shares) Outstanding at end of period (in shares) Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Number Accumulated Deficit Retained Earnings [Member] Debt Instrument [Axis] Debt Instrument [Axis] Prepaid expenses and other assets Increase (Decrease) in Prepaid Expense and Other Assets Warrants issued to purchase common stock (in shares) Class Of Warrant Or Right Warrants Issued During Period The number of warrants issued during the period. Contingencies Commitments and Contingencies Disclosure [Text Block] Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table] Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table] Automatic renewal period of agreement Automatic Renewal Period of Agreement Period for which the agreement is renewed automatically. Grant date fair value of shares vested during the period Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments, Other Than Options Grants, Estimated Grant Date Fair Value The estimated fair value of nonvested equity-based awards on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan) as of grant date. Warrants [Abstract] Warrants Liability [Abstract] Property, Plant and Equipment [Line Items] Property, Plant and Equipment [Line Items] Commitments and Contingencies Disclosure [Abstract] Commitments and Contingencies Disclosure [Abstract] Change in fair value of warrant Adjustments to Additional Paid in Capital, Fair Value of Warrants Issued Amount of increase in additional paid in capital (APIC) resulting from the issuance of fair value of warrants. Includes allocation of proceeds of debt securities issued with detachable stock purchase warrants. Balance at December 31, 2021 Balance at March 31, 2022 Accounts Receivable Allowances and Accruals For an unclassified balance sheet, a valuation of sales allowance for receivables due a company that are expected to be uncollectible and accruals. Deferred revenue Increase (Decrease) in Deferred Revenue Net loss per share - basic (in dollars per share) Loss per common share - basic (in dollars per share) Earnings Per Share, Basic Other non-current Assets Other Assets Disclosure [Text Block] Number of cases pending Loss Contingency, Pending Claims, Number 2025 Lessee, Operating Lease, Liability, to be Paid, Year Three Revenues and Trade Receivables, Net Revenues and Trade Receivables, Net [Text Block] The entire disclosure of revenues and trade receivables, net. Unvested, at beginning of period (in shares) Unvested, at end of period (in shares) Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Number 2023 Long-Term Debt, Maturity, Year One Indivior Commercial Exploitation Agreement with Indivior Commercial Exploitation Agreement with Indivior [Member] The commercial exploitation agreement with Indivior. Disaggregation of Revenue Disaggregation of Revenue [Table Text Block] Raw material Inventory, Raw Materials, Gross Number of Units Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Number of Shares [Roll Forward] Restricted Stock Units Awards Nonvested Restricted Stock Shares Activity [Table Text Block] Machinery Machinery and Equipment [Member] Supplemental Agreement with Indivior Additional Process Patent Rights to the Company Supplemental Agreement with Indivior Additional Process Patent Rights to the Company [Member] The supplemental commercial exploitation agreement with Indivior earnings through the issuance of additional process patent rights to the company. Other, net Other Noncash Income (Expense) Accounts Receivable Allowances and Accruals [Roll Forward] Accounts Receivable Allowances and Accruals [Roll Forward] Accounts Receivable Allowances and Accruals Additions charged to expense Accounts Receivable, Credit Loss Expense (Reversal) Plan Name [Axis] Plan Name [Axis] Long-term debt Total Long-term Debt Proprietary product sales, net Proprietary Product Sales [Member] The aggregate revenue generated from proprietary product sales. Investing activities: Net Cash Provided by (Used in) Investing Activities [Abstract] Income Tax Disclosure [Abstract] Income Tax Disclosure [Abstract] Entity Small Business Entity Small Business Finite-Lived Intangible Assets [Line Items] Finite-Lived Intangible Assets [Line Items] Total liabilities and stockholders’ deficit Liabilities and Equity Other Other Accrued Liabilities, Current Deferred revenue, current Contract with Customer, Liability, Current Scenario [Axis] Scenario [Axis] License and royalty revenue License and Royalty Revenue [Member] The aggregate revenue generated from licensing and royalties. Trade and other receivables, net Increase (Decrease) in Accounts and Other Receivables Additional paid-in capital Additional Paid in Capital Liability related to the sale of future revenue, net Transfer Of Financial Assets, Accounted For As Sales, Amount Derecognized, Noncurrent Transfer Of Financial Assets, Accounted For As Sales, Amount Derecognized, Noncurrent Lessee, Lease, Description [Table] Lessee, Lease, Description [Table] Neurelis IPR Litigation Neurelis IPR Litigation [Member] Neurelis IPR Litigation Manufacture and supply revenue Manufacture and Supply Revenue [Member] The aggregate revenue generated from manufacture and supply. Concentration Risk [Line Items] Concentration Risk [Line Items] Liabilities and stockholders’ deficit Liabilities and Equity [Abstract] Proceeds from issuance of common stock, net Proceeds from Issuance Initial Public Offering Accounts payable Increase (Decrease) in Accounts Payable Net Loss Per Share Earnings Per Share [Text Block] Costs and expenses: Operating Expenses [Abstract] Entity Interactive Data Current Entity Interactive Data Current Option Indexed to Issuer's Equity, Type [Domain] Option Indexed to Issuer's Equity, Type [Domain] Minimum Minimum [Member] Percentage of cash proceeds Repurchase Offer, Percentage of Cash Proceeds Received Repurchase Offer, Percentage of Cash Proceeds Received 2024 Lessee, Operating Lease, Liability, to be Paid, Year Two Balance Sheet Location [Domain] Balance Sheet Location [Domain] Class of Warrant or Right [Line Items] Class of Warrant or Right [Line Items] Selling, general and administrative Selling, General and Administrative Expense Research and Development, Project Duration Research and Development, Project Duration Research and Development, Project Duration Entity Common Stock, Shares Outstanding Entity Common Stock, Shares Outstanding Interest expense related to the sale of future revenue, net Interest Expense, Sale of Future Revenues Interest Expense, Sale of Future Revenues Minimum annual royalty receivable Minimum Annual Royalty Receivable Minimum annual royalty receivable by the entity for the use of its rights and property by another party. Entity Address, State or Province Entity Address, State or Province Number of states in the antitrust litigation Number of states in the antitrust litigation The number of states in the antitrust litigation. Interest expense related to the sale of future revenue, net Interest expense related to the sale of future revenue Interest Expense, Sale of Future Revenues (Excluding Amortization) Interest Expense, Sale of Future Revenues (Excluding Amortization) Revenues and Trade Receivables, Net [Abstract] Revenues and Trade Receivables, Net [Abstract] Current liabilities: Liabilities, Current [Abstract] Class of Warrant or Right [Table] Class of Warrant or Right [Table] Common Stock issued under public equity offering Stock Issued During Period, Value, New Issues 12.5% Senior Secured Notes and Loans Payable Debt Disclosure [Text Block] Balance (in shares) Balance (in shares) Shares, Outstanding Share-Based Compensation Share-based Payment Arrangement [Text Block] Senior Notes Senior Notes [Member] Inventories, Net Inventory Disclosure [Text Block] Accounting Policies [Abstract] Accounting Policies [Abstract] Payments for stock issuance costs Payments of Stock Issuance Costs Common Stock issued under public equity offering (in shares) Stock Issued During Period, Shares, New Issues Warrants Warrants Disclosure [Text Block] The entire disclosure for warrants. Senior Secured Notes Due 2025 - Second Additional Offering Second Additional Offering [Member] The second additional offering of the loan agreement. Total operating lease liabilities Operating Lease, Liability Revenue Revenue from External Customers by Products and Services [Table Text Block] Document Transition Report Document Transition Report Common stock, $0.001 par value. Authorized 250,000,000 shares; 41,620,388 and 41,228,736 shares issued and outstanding at March 31, 2022 and December 31, 2021, respectively Common Stock, Value, Issued Disaggregation of Revenue [Line Items] Disaggregation of Revenue [Line Items] Unrecognized compensation cost, recognition period Share-based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition Unvested, at beginning of period (in dollars per share) Unvested, at end of period (in dollars per share) Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value Customer Concentration Risk Customer Concentration Risk [Member] Basis of Presentation Basis of Accounting, Policy [Policy Text Block] Contingencies (Note 19) Commitments and Contingencies Supplemental Agreement with Indivior Supplemental Agreement with Indivior [Member] The supplemental commercial exploitation agreement with Indivior. Subsequent Event [Table] Subsequent Event [Table] Right-of-Use Assets and Lease Obligations Lessee, Operating Leases [Text Block] Entity Emerging Growth Company Entity Emerging Growth Company Remainder of 2022 Lessee, Operating Lease, Liability, to be Paid, Remainder of Fiscal Year Sale of Future Revenue [Roll Forward] Sale of Future Revenue [Roll Forward] Sale of Future Revenue Valuation Assumptions for Determination of Fair Value of Options Schedule of Share-based Payment Award, Stock Options, Valuation Assumptions [Table Text Block] Proceeds from refinancing of debt Proceeds from Issuance of Debt Summary of Other Non-current Assets Schedule of Other Assets, Noncurrent [Table Text Block] Antidilutive Securities, Name [Domain] Antidilutive Securities, Name [Domain] License agreement term License Agreement Term License agreement term period. Cover [Abstract] Cover [Abstract] Total costs and expenses Costs and Expenses Sales Related Allowances and Accruals Sales Related Allowances and Accruals [Table Text Block] Tabular disclosure of valuation of sales allowance and accruals for receivables due a company that are expected to be uncollectible including a rollforward of the balance. Notice period of intent not to renew agreement Notice Period for Not to Renew Agreement Notice period of intent not to renew agreement, prior to the expiration of the initial or renewal term. Number of products approved by Food and Drug Administration Number Of Products Approved By Food And Drug Administration Number Of Products Approved By Food And Drug Administration Collaborative Arrangement and Arrangement Other than Collaborative [Axis] Collaborative Arrangement and Arrangement Other than Collaborative [Axis] Less: imputed interest Lessee, Operating Lease, Liability, Undiscounted Excess Amount Contract with Customer, Contract Asset, Contract Liability, and Receivable [Abstract] Contract with Customer, Contract Asset, Contract Liability, and Receivable [Abstract] Subsidiary or Equity Method Investee, Sale of Stock by Subsidiary or Equity Investee [Table] Subsidiary or Equity Method Investee, Sale of Stock by Subsidiary or Equity Investee [Table] Consideration received on sale of stock Sale of Stock, Consideration Received on Transaction Number of quarterly payments Debt Instrument, Principal, Number Of Quarterly Payments Debt Instrument, Principal, Number Of Quarterly Payments Payments / credits Accounts Receivable Allowances, Credits and payments For an unclassified balance sheet, a valuation of sales allowance for receivables related to credits due a company that are expected to be uncollectible. Prepaid expenses and other current assets Prepaid Expense and Other Assets, Current Accrued expenses Total accrued expenses Accrued Liabilities, Current Revenues Royalties related to the sale of future revenue Revenue from Contract with Customer, Excluding Assessed Tax Marathon Pangolin Royalty LLC Marathon Pangolin Royalty LLC [Member] Marathon Pangolin Royalty LLC Options on Common Shares Outstanding Stock options Share-based Payment Arrangement, Option [Member] Document Quarterly Report Document Quarterly Report Exercised, Forfeited, Expired (in dollars per share) Share Based Compensation Arrangement By Share Based Payment Award Options Exercised Forfeitures And Expirations In Period WeightedAverageExercisePrice Weighted average price of options that were either exercised, forfeited or expired. Common Stock Common Stock [Member] Loss from operations Operating Income (Loss) Property, Plant and Equipment [Table] Property, Plant and Equipment [Table] Fair value of warrants Warrants Not Settleable in Cash, Fair Value Disclosure Lease liabilities, current Operating Lease, Liability, Current Company Overview and Basis of Presentation Organization, Consolidation and Presentation of Financial Statements Disclosure and Significant Accounting Policies [Text Block] License Agreement with Sunovion Pharmaceuticals, Inc. Upfront License Agreement with Sunovion Pharmaceuticals, Inc. Upfront [Member] The license agreement made with sunovion pharmaceuticals, inc. advance payments. Material Agreements Collaborative Arrangement Disclosure [Text Block] Increase (Decrease) in Stockholders' Equity [Roll Forward] Increase (Decrease) in Stockholders' Equity [Roll Forward] Document Fiscal Year Focus Document Fiscal Year Focus Property, Plant and Equipment [Abstract] Property, Plant and Equipment [Abstract] Share-based compensation Share-based Payment Arrangement, Noncash Expense Additional Paid-in Capital Additional Paid-in Capital [Member] Cash and cash equivalents Cash and Cash Equivalents, at Carrying Value Depreciation and amortization Depreciation Repayment of debt Repayments of Debt Schedule of Acquired Finite-Lived Intangible Asset by Major Class [Table] Schedule of Acquired Finite-Lived Intangible Asset by Major Class [Table] Purchased technology-based intangible Technology-Based Intangible Assets [Member] Senior Secured Notes Due 2025 Twelve Point Five, Senior Secured Notes due June 30, 2025 [Member] A debt arrangement having an initial term longer than one year or beyond the normal operating cycle, if longer. Cardinal Cardinal [Member] Cardinal Long-term Debt, Type [Domain] Long-term Debt, Type [Domain] Number of leases Number of Operating Leases Number of operating leases. Collaborative Arrangement and Arrangement Other than Collaborative [Domain] Collaborative Arrangement and Arrangement Other than Collaborative [Domain] Warrants issued (in shares) Class of Warrant or Right, Number of Securities Called by Warrants or Rights Fair value of put option Long-term Debt, Fair Value Capital expenditures Payments to Acquire Property, Plant, and Equipment Maximum Maximum [Member] Share-based Payment Arrangement [Abstract] Share-based Payment Arrangement [Abstract] Total liabilities Liabilities Prepayment premiums paid Payment for Debt Extinguishment or Debt Prepayment Cost Award Type [Axis] Award Type [Axis] Granted (in dollars per share) Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price Financing activities: Net Cash Provided by (Used in) Financing Activities [Abstract] Number of causes alleged Cause of Action, Number Number of causes of action. Exercisable at end of period (in dollars per share) Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Exercisable, Weighted Average Exercise Price Operating Lease Liabilities Lessee, Operating Lease, Liability, Maturity [Table Text Block] Total stockholders’ deficit Balance Balance Stockholders' Equity Attributable to Parent Common stock, shares issued (in shares) Common Stock, Shares, Issued City Area Code City Area Code Goodwill and Intangible Assets Disclosure [Abstract] Goodwill and Intangible Assets Disclosure [Abstract] Entity Address, City or Town Entity Address, City or Town Interest and other expense, net Gain (Loss) on Extinguishment of Debt Other Other Assets, Miscellaneous, Noncurrent Trade receivables Accounts Receivable, before Allowance for Credit Loss Useful Lives Property, Plant and Equipment, Useful Life Trade and other receivables, net Trade and other receivables, net Trade and other receivables, net Amount due from customers or clients, within one year of the balance sheet date (or the normal operating cycle, whichever is longer), for goods or services (including trade and other receivables). Stockholders’ deficit: Stockholders' Equity Attributable to Parent [Abstract] Share-based Compensation expenses [Abstract] Share-based Payment Arrangement, Noncash Expense [Abstract] Share-Based Compensation Equity Awards [Abstract] Share-Based Compensation Equity Awards [Abstract] Balance Sheet Location [Axis] Balance Sheet Location [Axis] Manufacture and supply Manufacturing and supply [Member] Primary financial statement caption encompassing Manufacturing and supply expense. Lease liabilities Operating Lease, Liability, Noncurrent Accounting Standards Update [Axis] Accounting Standards Update [Axis] Accounting Standards Update 2016-02 Accounting Standards Update 2016-02 [Member] Principal amount Debt Instrument, Face Amount Interest expense Interest Expense Effective annual interest rate Debt Instrument, Interest Rate, Effective Percentage Share price (in dollars per share) Share Price Accumulated deficit Accumulated deficit Retained Earnings (Accumulated Deficit) Litigation Case [Domain] Litigation Case [Domain] Restricted stock units Restricted Stock Units (RSUs) [Member] Statement of Stockholders' Equity [Abstract] Statement of Stockholders' Equity [Abstract] Entity Filer Category Entity Filer Category Remaining lease term Lessee, Operating Lease, Remaining Lease Term Risk-free interest rate Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate Income Statement [Abstract] Income Statement [Abstract] Concentration Risk [Table] Concentration Risk [Table] Entity Registrant Name Entity Registrant Name Inventory Disclosure [Abstract] Inventory Disclosure [Abstract] Sale of Future Revenue Sale of Future Revenue [Text Block] Sale of Future Revenue Packaging material Inventory Packing Material Gross Amount of packaging materials expected to be sold within one year or operating cycle, if longer. Finite-Lived Intangible Assets by Major Class [Axis] Finite-Lived Intangible Assets by Major Class [Axis] Income taxes Income Tax Expense (Benefit) Amendment Flag Amendment Flag Changes in Allowance for Bad Debt Financing Receivable, Current, Allowance for Credit Loss [Table Text Block] Equity Components [Axis] Equity Components [Axis] Entity Tax Identification Number Entity Tax Identification Number Fair Value Disclosures [Abstract] Fair Value Disclosures [Abstract] Antidilutive Securities [Axis] Antidilutive Securities [Axis] Document Fiscal Period Focus Document Fiscal Period Focus Total current assets Assets, Current Total future lease payments Lessee, Operating Lease, Liability, to be Paid Concentration Risk Type [Domain] Concentration Risk Type [Domain] Receivables Accounts Receivable [Member] Disaggregation of Revenue [Table] Disaggregation of Revenue [Table] Sale of Stock [Domain] Sale of Stock [Domain] Forfeited (in shares) Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Forfeited in Period Principal payments, percentage of face amount Principal Payments, Percentage of Face Amount Principal Payments, Percentage of Face Amount Inventories, net Total inventory, net Inventory, Net Humana and Centene Actions Humana and Centene Actions [Member] Information by type of judicial proceeding, alternative dispute resolution or claim. Statement of Financial Position [Abstract] Statement of Financial Position [Abstract] Haisco Pharmaceutical Group Co., Ltd, Upfront Payment Haisco Pharmaceutical Group Co., Ltd, Upfront Payment [Member] Haisco Pharmaceutical Group Co., Ltd, Upfront Payment Unrecognized compensation expense related to non-vested stock options Share-based Payment Arrangement, Nonvested Award, Option, Cost Not yet Recognized, Amount Product and Service [Axis] Product and Service [Axis] Long-Lived Tangible Asset [Domain] Long-Lived Tangible Asset [Domain] Accounts Receivable, Allowance for Credit Loss [Roll Forward] Accounts Receivable, Allowance for Credit Loss [Roll Forward] Unrecognized compensation costs of RSU awards Share-based Payment Arrangement, Nonvested Award, Excluding Option, Cost Not yet Recognized, Amount Revenue Revenue Benchmark [Member] Weighted average grant date fair value (in dollars per share) Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value Equity Component [Domain] Equity Component [Domain] Other Stockholders' Equity, Other 2023 Lessee, Operating Lease, Liability, to be Paid, Year One Accrued expenses and other liabilities Increase (Decrease) in Accrued Liabilities and Other Operating Liabilities Provision Accounts Receivable Allowances, Provision (Reversal) Related to Sales For an unclassified balance sheet, a valuation of sales allowance for receivables related to sales due a company that are expected to be uncollectible. Geographic Areas, Revenues from External Customers [Abstract] Geographic Areas, Revenues from External Customers [Abstract] Statement [Line Items] Statement [Line Items] Litigation Case [Axis] Litigation Case [Axis] Agreement to Terminate CLA with KemPharm Agreement to Terminate CLA with KemPharm [Member] The agreement to terminate CLA with KemPharm. Weighted Average Exercise Price Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price [Abstract] Net proceeds from issuance of initial notes, warrants and first offer rights Net Proceeds from Issuance of Initial Notes, Warrants and First Offer Rights The net cash inflow associated with the amount received from issuance of initial notes, warrants and first offer rights. Share-based Compensation Expense Share-based Payment Arrangement, Cost by Plan [Table Text Block] 2026 Lessee, Operating Lease, Liability, to be Paid, Year Four Debt Disclosure [Abstract] Debt Disclosure [Abstract] Compensation Cost Not yet Recognized [Abstract] Share-based Payment Arrangement, Nonvested Award, Cost Not yet Recognized [Abstract] Net loss before income taxes Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest Accounting Standards Update [Domain] Accounting Standards Update [Domain] Long-Lived Tangible Asset [Axis] Long-Lived Tangible Asset [Axis] Subsidiary, Sale of Stock [Line Items] Subsidiary, Sale of Stock [Line Items] Deferred revenue Contract with Customer, Liability, Noncurrent Material Agreements [Abstract] Material Agreements [Abstract] Customer [Axis] Customer [Axis] Loans payable, net Loans Payable, Noncurrent Granted (in shares) Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross Basic and Diluted Net Loss Per Share Schedule of Earnings Per Share, Basic and Diluted [Table Text Block] Forecast Forecast [Member] Entity Ex Transition Period Entity Ex Transition Period Title of 12(b) Security Title of 12(b) Security Total assets Assets Plan Name [Domain] Plan Name [Domain] Common stock, shares authorized (in shares) Common Stock, Shares Authorized Cash payments for interest Interest Paid, Excluding Capitalized Interest, Operating Activities Numerator: Net Income (Loss) Attributable to Parent [Abstract] Geographical [Domain] Geographical [Domain] Document Type Document Type Additional Disclosures [Abstract] Share-based Compensation Arrangement by Share-based Payment Award, Additional General Disclosures [Abstract] Product and Service [Domain] Product and Service [Domain] Research and development Research and Development Expense Depreciation, amortization, and impairment Depreciation, Depletion and Amortization, Nonproduction Haisco Haisco Pharmaceutical Group Co., Ltd [Member] Haisco Pharmaceutical Group Co., Ltd Trade and Other Receivables, Net Schedule of Accounts, Notes, Loans and Financing Receivable [Table Text Block] Interest rate Debt Instrument, Interest Rate, Stated Percentage Share-based Compensation Arrangement by Share-based Payment Award [Line Items] Share-based Compensation Arrangement by Share-based Payment Award [Line Items] License Agreement with Sunovion Pharmaceuticals, Inc. License Agreement with Sunovion Pharmaceuticals, Inc. [Member] The license agreement made with sunovion pharmaceuticals, inc. Summary of Significant Accounting Policies Significant Accounting Policies [Text Block] Net cash used for operating activities Net Cash Provided by (Used in) Operating Activities Furniture and fixtures Furniture and Fixtures [Member] Schedule of Long-term Debt Instruments [Table] Schedule of Long-term Debt Instruments [Table] Subsequent Event [Line Items] Subsequent Event [Line Items] Geographical [Axis] Geographical [Axis] Weighted-average number of common shares outstanding - basic (in shares) Weighted-average number of common shares - basic (in shares) Weighted Average Number of Shares Outstanding, Basic Net loss per share - diluted (in dollars per share) Loss per common share - diluted (in dollars per share) Earnings Per Share, Diluted Amortization of debt issuance costs and discounts Amortization expense, deferred debt issuance costs and debt discounts Amortization of Debt Issuance Costs and Discounts Ex-United States Non-US [Member] Subsequent Events Subsequent Events [Text Block] Remaining amount available for offering Sale Of Stock, Remaining Amount Available For Offering Sale Of Stock, Remaining Amount Available For Offering Comprehensive loss Comprehensive Income (Loss), Net of Tax, Attributable to Parent Supplemental Agreement with Indivior Performance or Event-Based Milestones Supplemental Agreement with Indivior Performance or Event-Based Milestones [Member] The supplemental commercial exploitation agreement with Indivior. Contract liabilities Contract with Customer, Liability Accrued Expenses Accrued Expenses [Member] Accrued Expenses Net cash provided by financing activities Net Cash Provided by (Used in) Financing Activities Denominator: Weighted Average Number of Shares Outstanding, Diluted [Abstract] Other Noncurrent Liabilities Other Noncurrent Liabilities [Member] Amount of consideration on sale of stock agreement Sale Of Stock Agreement, Amount Of Consideration Sale Of Stock Agreement, Amount Of Consideration Co-development and research fees Co-Development and Research Fees [Member] The aggregate revenue generated from Co-development and research fees. Financial Instruments - Fair Value Measurements Fair Value Disclosures [Text Block] Receivable Contract with Customer, Receivable, after Allowance for Credit Loss Accounts payable Accounts Payable, Current Neurelis, Inc. v. Aquestive Therapeutics, Inc. Neurelis, Inc. v. Aquestive Therapeutics, Inc. [Member] Neurelis, Inc. v. Aquestive Therapeutics, Inc. Concentration Risk Type [Axis] Concentration Risk Type [Axis] Contingent payments receivable in the future Contingent payments receivable in the future Potential additional payment receivable under the agreement as of the balance sheet date. These are the aggregate from any combination of (a) performance or event-based milestone payments and (b) single digit percentage royalties on net revenue earned by Indivior on sales of Suboxone and earnings through the issuance of additional process patent rights to the company. Exercised, Forfeited, Expired (in shares) Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercised,Forfeitures and Expirations in Period For presentations that combine terminations, the number of shares under options that were exercised, cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan or that expired. 2022 Finite-Lived Intangible Asset, Expected Amortization, Remainder of Fiscal Year Inventories, net Increase (Decrease) in Inventories Common stock, shares outstanding (in shares) Common Stock, Shares, Outstanding Licensed Product Licensed Product [Member] Licensed Product Manufacture and supply Cost of Goods and Services Sold Equity Distribution Agreement Equity Distribution Agreement [Member] Equity Distribution Agreement Document Period End Date Document Period End Date Entity Central Index Key Entity Central Index Key Concentration Risk Benchmark [Domain] Concentration Risk Benchmark [Domain] Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items] Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items] Number of Options Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding [Roll Forward] Property and Equipment, Net Property, Plant and Equipment [Table Text Block] Income Statement Location [Domain] Income Statement Location [Domain] Loss Contingencies [Line Items] Loss Contingencies [Line Items] Risks and Uncertainties Concentration Risk Disclosure [Text Block] Property and equipment, net Total property and equipment, net Property, Plant and Equipment, Net Property and Equipment, Net Property, Plant and Equipment Disclosure [Text Block] Warrants and Rights Note Disclosure [Abstract] Warrants and Rights Note Disclosure [Abstract] Other non-current liabilities Other Liabilities, Noncurrent Costs of common stock issued under public equity offering Adjustments to Additional Paid in Capital, Stock Issued, Own-share Lending Arrangement, Issuance Costs Debt Instrument [Line Items] Debt Instrument [Line Items] Trading Symbol Trading Symbol Earnings Per Share [Abstract] Earnings Per Share [Abstract] Property and equipment, gross Property, Plant and Equipment, Gross Accrued Expenses Accounts Payable and Accrued Liabilities Disclosure [Text Block] Less: allowance for doubtful accounts Allowance for doubtful accounts at beginning of the period Allowance for doubtful accounts at end of the period Accounts Receivable, Allowance for Credit Loss Warrant exercise price (in dollars per share) Class of Warrant or Right, Exercise Price of Warrants or Rights Vested or expected to vest at end of period (in shares) Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding, Number Employee Stock Purchase Plan Employee Stock Purchase Plan [Member] The Employee Stock Purchase Plan (the "ESPP") allows eligible full-time employees to purchase shares of common stock at 90 percent of the lower of the fair market value of a share of common stock on the first or last day of the quarter. Finished goods Inventory, Finished Goods, Gross Proceeds from sale of future revenue Proceeds From Sale of Future Revenues, Net Proceeds From Sale of Future Revenues, Net Outstanding at beginning of period (in dollars per share) Outstanding at end of period (In dollars per share) Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price Warrants on Common Shares Outstanding Warrant [Member] Sale of stock term Sale Of Stock Agreement, Term Sale Of Stock Agreement, Term 12.5% Senior Secured Notes [Abstract] Senior Secured Notes [Abstract] Redemption percentage of debt under change of control provisions Redemption percentage of debt under change of control provisions Redemption percentage of debt under change of control provisions. Purchased patent Patents [Member] Share-based compensation expenses Share-based Payment Arrangement, Expense Entity Current Reporting Status Entity Current Reporting Status Weighted Average Grant Date Fair Value Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value [Abstract] Monetization Agreement Monetization Agreement [Member] Monetization Agreement Amortization of issuance costs Amortization of Debt Issuance Costs Payables and Accruals [Abstract] Payables and Accruals [Abstract] Construction in progress Construction in Progress [Member] Cash and cash equivalents at beginning of period Cash and cash equivalents at end of period Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents United States UNITED STATES Number of shares issued in transaction (in shares) Sale of Stock, Number of Shares Issued in Transaction Common stock, par value (in dollars per share) Common Stock, Par or Stated Value Per Share Real estate and personal property taxes Taxes Payable, Current Current assets: Assets, Current [Abstract] Intangible assets, gross Finite-Lived Intangible Assets, Gross Leases [Abstract] Leases [Abstract] License Agreement with Sunovion Pharmaceuticals, Inc Milestones License Agreement with Sunovion Pharmaceuticals, Inc Milestones [Member] The license agreement made with sunovion pharmaceuticals, inc. milestones. Finite-Lived Intangible Assets, Net [Abstract] Finite-Lived Intangible Assets, Net [Abstract] Components of Identifiable Intangible Assets Schedule of Finite-Lived Intangible Assets [Table Text Block] Entity Address, Postal Zip Code Entity Address, Postal Zip Code Accrued Expenses Schedule of Accounts Payable and Accrued Liabilities [Table Text Block] Less: sales-related allowances Accrued balances - Trade and other receivables, net Accounts Receivable Allowances and Accruals - Trade and Other Receivables, Net For an unclassified balance sheet, a valuation of sales allowance for receivables due a company that are expected to be uncollectible, classified within trade and other receivables, net. Revenue Recognition and Performance Obligations Revenue from Contract with Customer [Policy Text Block] Guaranteed royalty period Period Of Guaranteed Royalty Period Of Guaranteed Royalty Weighted-average number of common shares outstanding - diluted (in shares) Weighted Average Number of Shares Outstanding, Diluted Liability related to the sale of future revenue, current Transfer Of Financial Assets, Accounted For As Sales, Amount Derecognized, Current Transfer Of Financial Assets, Accounted For As Sales, Amount Derecognized, Current Income Taxes Income Tax Disclosure [Text Block] Long-term Debt, Type [Axis] Long-term Debt, Type [Axis] Stock Option Activity Share-based Payment Arrangement, Option, Activity [Table Text Block] Write-downs charged against the allowance Accounts Receivable, Allowance for Credit Loss, Writeoff Statement of Cash Flows [Abstract] Statement of Cash Flows [Abstract] Other expenses: Nonoperating Income (Expense) [Abstract] Estimated discount rate Lessee, Operating Lease, Discount Rate Royalty Royalty [Member] Finite-Lived Intangible Assets, Major Class Name [Domain] Finite-Lived Intangible Assets, Major Class Name [Domain] Credit Facility [Axis] Credit Facility [Axis] Entity Address, Address Line One Entity Address, Address Line One Option Indexed to Issuer's Equity, Type [Axis] Option Indexed to Issuer's Equity, Type [Axis] Net cash used for investing activities Net Cash Provided by (Used in) Investing Activities Proceeds from debt, contingent on additional milestones Contingent Monetization Agreement, Milestone Payment Contingent Monetization Agreement, Milestone Payment Revenue [Abstract] Disaggregation of Revenue [Abstract] Contract assets Contract and other receivables Other Receivables, Gross, Current Changes in operating assets and liabilities: Increase (Decrease) in Operating Capital [Abstract] Less: accumulated depreciation and amortization Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment At-the-Market Offering, Amendment No. 1 At The Market Offering, Amendment One [Member] At The Market Offering, Amendment One Operating activities: Net Cash Provided by (Used in) Operating Activities [Abstract] Vested (in dollars per share) Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Vested in Period, Weighted Average Grant Date Fair Value Selling, general and administrative General and Administrative Expense [Member] Entity Shell Company Entity Shell Company Expected term (years) Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Term Total current liabilities Liabilities, Current Additional borrowing capacity Debt Instrument, Additional Borrowing Capacity Amount of debt that can be borrowed in addition to initial notes. Current portion Liabilities, Sale of Future Royalties, Current Liabilities, Sale of Future Royalties, Current Loss Contingencies [Table] Loss Contingencies [Table] Current Fiscal Year End Date Current Fiscal Year End Date Unamortized deferred debt issuance cost and deferred debt discounts Debt Instrument, Unamortized Discount (Premium) and Debt Issuance Costs, Net Debt Instrument, Name [Domain] Debt Instrument, Name [Domain] Statement [Table] Statement [Table] Customer Concentration [Abstract] Customer Concentration [Abstract] Collaborative Arrangement and Arrangement Other than Collaborative [Table] Collaborative Arrangement and Arrangement Other than Collaborative [Table] Recent Accounting Pronouncements New Accounting Pronouncements, Policy [Policy Text Block] Fair Value Assumptions [Abstract] Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions and Methodology [Abstract] Statistical Measurement [Axis] Statistical Measurement [Axis] Subsequent Event Subsequent Event [Member] Intangible assets, net Intangible assets, net Finite-Lived Intangible Assets, Net Scenario [Domain] Scenario [Domain] Adjustments to reconcile net loss to net cash used for operating activities: Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract] Subsequent Event Type [Axis] Subsequent Event Type [Axis] Sale of stock, aggregate offering price Sale of Stock, Aggregate Offering Price Sale of Stock, Aggregate Offering Price Operating lease expense Operating Lease, Cost Concentration Risk Benchmark [Axis] Concentration Risk Benchmark [Axis] Schedule of Finite-Lived Intangible Assets [Table] Schedule of Finite-Lived Intangible Assets [Table] Collaborative Arrangement and Arrangement Other than Collaborative [Line Items] Collaborative Arrangement and Arrangement Other than Collaborative [Line Items] Payments of loan costs Payments of Loan Costs